← Leaderboards
Alexandros Tzatsos
Massachusetts General Hospital
$3,506,089
Attributed
$3,506,089
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $444.6K · FY2011–22$500K$375K$250K$125K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$3,506,089 · 6
By mechanism
R01$1,806,036 · 1
R00$706,922 · 1
R21$374,323 · 1
R03$319,000 · 2
K99$299,808 · 1
Top collaborators
No co-investigators on record.
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Katia Georgopoulos$27,357,145
- David Michael Langenau$26,574,494
- Jessica Elizabeth Stewart Shay$331,526
- Hua-Ying Fan$3,825,645
- Christopher Holmes Newton-Cheh$8,878,611
Others in their field
Top investigators on “Mutation”
- Richard A Gibbs · Baylor College Of Medicine$276,143,183
- David Heimbrook · Leidos Biomedical Research, Inc.$175,834,894
- Randall J Bateman · Washington University$154,391,630
- Eric Martin McDade · Washington University$96,219,353
- Stacey Gabriel · Massachusetts Institute Of Technology$95,141,374
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$93,475,056
Research focus
MutationEpigenetic ProcessTumor Suppressor ProteinsMalignant NeoplasmsGenetically Engineered MouseEnzymesCellsHistonesMolecularChromatinProgramsOncogenicGenesMalignant Neoplasm Of PancreasCessation Of LifeMouse ModelMediator Of Activation ProteinMadh4 GeneMapsCancer EtiologyNovel TherapeuticsMediatingKras2 GeneTumor Progression
Grant awards (16)
Deregulation of COMPASS complex and enhancer chromatin in pancreatic cancer$357,559
R01 · FY2022 · CA · contact PI
Deregulation of COMPASS complex and enhancer chromatin in pancreatic cancer$364,856
R01 · FY2021 · CA · contact PI
Deregulation of COMPASS complex and enhancer chromatin in pancreatic cancer$364,856
R01 · FY2020 · CA · contact PI
Identifying and targeting epigenetic vulnerabilities in NOTCH1 driven leukemia$79,750
R03 · FY2020 · CA · contact PI
Deregulation of COMPASS complex and enhancer chromatin in pancreatic cancer$353,909
R01 · FY2019 · CA · contact PI
Identifying and targeting epigenetic vulnerabilities in NOTCH1 driven leukemia$79,750
R03 · FY2019 · CA · contact PI
Deregulation of COMPASS complex and enhancer chromatin in pancreatic cancer$364,856
R01 · FY2018 · CA · contact PI
Epigenetic regulation of metabolic rerpogramming in pancreatic cancer$79,750
R03 · FY2018 · CA · contact PI
Epigenetic regulation of metabolic rerpogramming in pancreatic cancer$79,750
R03 · FY2017 · CA · contact PI
Role of epigenetic regulators in pancreatic cancer$229,693
R00 · FY2016 · CA · contact PI
Role of epigenetic regulators in pancreatic cancer$235,699
R00 · FY2015 · CA · contact PI
Elucidating and targeting epigenetic oncogenic networks in pancreatic cancer$206,843
R21 · FY2015 · CA · contact PI
Role of epigenetic regulators in pancreatic cancer$241,530
R00 · FY2014 · CA · contact PI
Elucidating and targeting epigenetic oncogenic networks in pancreatic cancer$167,480
R21 · FY2014 · CA · contact PI
Role of epigenetic regulators in pancreatic cancer$149,904
K99 · FY2012 · CA · contact PI
Role of epigenetic regulators in pancreatic cancer$149,904
K99 · FY2011 · CA · contact PI